By Denny Jacob
Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals.
Shares were trading around $120.01. The stock is up 8.3% over the last year.
The commercial-stage biopharmaceutical company said the settlement resolves all patent litigation related to its Auvelity bupropion product. The litigation resulted after Teva submitted an abbreviated new drug application to the Food and Drug Administration seeking approval to market a generic version of Auvelity in the U.S. prior to the expiration of applicable patents.
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after Sept. 30, 2039, if no pediatric exclusivity is granted.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 10, 2025 08:43 ET (13:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。